Related Experiment Videos
Preparation of genetically engineered monoclonal antibodies for human immunotherapy
1Central Laboratory, The Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Human Antibodies and Hybridomas
|July 1, 1992
Summary
Producing specific human monoclonal antibodies (MAbs) is challenging. Humanized MAbs, created using recombinant DNA, overcome rodent antibody antigenicity issues for improved immunotherapies.
Area of Science:
- Immunology
- Biotechnology
- Molecular Biology
Background:
- Conventional hybridoma technology faces difficulties in producing human monoclonal antibodies (MAbs) with precise specificity.
- The use of rodent MAbs in human immunotherapies is limited by their antigenicity, potentially triggering adverse human immune responses.
Purpose of the Study:
- To address the challenges in producing specific human MAbs.
- To develop strategies for creating less immunogenic antibodies for therapeutic applications.
Main Methods:
- Employing recombinant DNA techniques to transfer the specificity of rodent MAbs into human antibodies.
- Two primary approaches include combining rodent variable regions with human constant regions and "reshaping" human MAbs by grafting complementarity-determining regions (CDRs).
Main Results:
- Successful development of humanized MAbs by combining rodent and human antibody components.
- Humanized MAbs enable detailed investigation of human Fc-dependent effector mechanisms.
Conclusions:
- Humanized monoclonal antibodies offer a promising solution to overcome the immunogenicity of rodent antibodies in human therapies.
- These engineered antibodies are crucial for optimizing in vivo applications and studying effector functions.